Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 2,551 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Neurodevelopmental Disorder Clear all

Conditions: Pediatric Disorder, Disability, Developmental
Interventions: Hybrid of telehealth and in-person physical therapy services; Other
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 2 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Neurodevelopmental Disorders
Interventions: Game; Behavioral
Lead sponsor: Yale University; Other
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Autism Spectrum Disorder, Fragile X Syndrome
Interventions: Mismatch negativity; Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 15 Years to 35 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Attention-Deficit/Hyperactivity Disorder, ADHD
Interventions: ABT-894, atomoxetine, placebo; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 22
States / cities: San Francisco, California • Wildomar, California • Orlando, Florida + 19 more

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: Methylphenidate transdermal system, Lisdexamfetamine dimesylate, Osmotic-release oral system methylphenidate (OROS MPH), Mixed amphetamine salts extended release; Drug
Lead sponsor: Duke University; Other
Eligibility: 6 Years to 17 Years
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Autism, Autism Spectrum Disorder
Interventions: Being Brave; Behavioral
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 3 Years to 6 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Brookline, Massachusetts

Conditions: Attention Deficit Hyperactivity Disorder, Oppositional Defiant Disorder, Conduct Disorder
Interventions: Clinical Assessment Visit, fMRI scan; Diagnostic Test · Other
Lead sponsor: University of Michigan; Other
Eligibility: 6 Years to 18 Years
Enrollment: 256 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Autism Spectrum Disorder, Autism Spectrum Disorders, Autistic Disorder, Autism
Interventions: Prednisone, Placebo; Drug
Lead sponsor: Christopher John McDougle, M.D.; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Lexington, Massachusetts

Conditions: ADHD
Interventions: ADHD methylphenidate first, placebo second, ADHD placebo first, methylphenidate second, Non-ADHD methylphenidate first, placebo second, Non-ADHD placebo first, methylphenidate second; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 45 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Little Rock, Arkansas • Durham, North Carolina

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)
Interventions: Active TNS; Device
Lead sponsor: James McGough; Other
Eligibility: 8 Years to 13 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Microcephaly, Hyperkinesis With Developmental Delay, Global Developmental Delay
Interventions: Acquire Therapy; Behavioral
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 6 Months to 15 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Nicotine Dependence, ADHD
Interventions: Very low nicotine content cigarettes, Conventional nicotine content cigarettes; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Durham, North Carolina • Pittsburgh, Pennsylvania

Conditions: Attention-Deficit/Hyperactivity Disorder, Attention Deficit Disorder, Insomnia, Sleep Disorders
Interventions: Guanfacine extended-release tablets, Placebo comparator; Drug
Lead sponsor: Children's Specialized Hospital; Other
Eligibility: 6 Years to 12 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Hamilton, New Jersey • Toms River, New Jersey

Conditions: Autism Spectrum Disorder, Neurodevelopmental Disorders
Interventions: Remaking Recess, TEAM; Behavioral · Other
Lead sponsor: University of Washington; Other
Eligibility: 5 Years and older
Enrollment: 350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: Los Angeles, California • Eugene, Oregon • Seattle, Washington

Conditions: Implementation Research
Interventions: NDBIs; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)
Interventions: LDX 30 mg, LDX 50 mg, LDX 70 mg, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 45
States / cities: Little Rock, Arkansas • El Centro, California • Rolling Hills Estates, California + 40 more

Conditions: Autism Spectrum Disorder
Interventions: IGF-1, Placebo/saline; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 5 Years to 12 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Brain Training (Active), Brain Training (Passive), Brain Training (Active or Passive); Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 4 Years to 5 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Stanford, California

Conditions: Childhood Onset Psychotic Disorders, Schizophrenia
Interventions: Intranasal Oxytocin; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 10 Years to 99 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Schizophrenia, Bipolar I Disorder, Autism Spectrum Disorder (ASD)
Interventions: Cariprazine Flexible Dose; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 40
States / cities: Dothan, Alabama • Bentonville, Arkansas • Anaheim, California + 31 more

Conditions: Intellectual Disability, Down Syndrome
Interventions: Self-monitoring shopping intervention; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Hillsborough, New Jersey

Conditions: Autism Spectrum Disorder, EEG With Periodic Abnormalities, Epilepsy, Neurodevelopmental Disorders, Neurological Disorder
Interventions: noninvasively delivered near infra-red (NIR) light - transcranial Photobiomodulation (tPBM); Device
Lead sponsor: Richard Frye; Other
Eligibility: 4 Years to 16 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Neurodevelopmental Disorders
Interventions: Intensive therapy program; Other
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 4 Years to 15 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Autism
Interventions: Paliperidone ER; Drug
Lead sponsor: Indiana University; Other
Eligibility: 12 Years to 21 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Indianapolis, Indiana

Search by objective public record fields.

Hybrid Telehealth in Pediatric Physical Therapy

Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game

Speech-in-noise Perception in Autism and Fragile X

A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Comparing the Effectiveness of New Versus Older Treatments for Attention Deficit Hyperactivity Disorder (The NOTA Study)

Biomarkers Research in Anxiety for Validation and Efficacy

Study of Cognition and Control in Youths

Prednisone in Adults With an Immune-Mediated Subtype of Autism Spectrum Disorder

Motivated Behavior in Adults With and Without ADHD

12 Month Open Extension of TNS for ADHD.

Intensive Therapy for Children With Microcephaly, Hyperkinetic Movements, or Global Developmental Delay

Effects of Nicotine Reduction on Smoking Behavior in ADHD Smokers

Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia

School-based Paraeducator Education for Engagement at Recess

Implementation of Naturalistic Developmental Behavioral Intervention (NDBI) Through Coaching Caregivers of Young Autistic Children

Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum Disorder

Brain Training in Children With/At-risk for Attention-Deficit/Hyperactivity Disorder and Executive Function Impairment

Daily Intranasal Oxytocin for Childhood-Onset Schizophrenia

Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder

Self-Monitoring Shopping Intervention

Safety and Efficacy of tPBM for Epileptiform Activity in Autism

Experience With a Pediatric Summer Intensive Therapy Program

Study of Paliperidone ER in Adolescents and Young Adults With Autism